Perinatal cytomegalovirus and toxoplasmosis: Challenges of antepartum therapy

Keyphrases

• Antepartum 100%
• Cytomegalovirus 100%
• Toxoplasmosis 100%
• Congenital Toxoplasmosis 100%
• Congenital Infection 66%
• Long-term Sequelae 33%
• Neonatal Disease 33%
• Spontaneous Preterm Birth (sPTB) 33%
• Severe Disease 33%
• Primary Prevention 33%
• Secondary Prevention 33%
• Severe Visual Impairment 33%
• Gestational Age 33%
• Infection Rate 33%
• First Month 33%
• Titer 33%
• Intellectual Disability 33%
• Subclinical Infection 33%
• Diagnostic Criteria 33%
• Spasticity 33%
• Hydrocephalus 33%
• Lymphadenopathy 33%
• Seizure Disorder 33%
• Microcephaly 33%
• Maternal Infection 33%
• Palsy 33%
• Deafness 33%
• Chemoprophylaxis 33%
• Antenatal Treatment 33%
• Sabin-Feldman Dye Test 33%
• Intracranial Calcification 33%
• Pyrimethamine 33%
• Chronic Toxoplasmosis 33%
• Toxoplasmosis Infection 33%
• Fetal Infection 33%
• Undiagnosed Diseases 33%
• Spiramycin 33%
• IFA Test 33%
• Sulfonamides 33%

Medicine and Dentistry

• Cytomegalovirus 100%
• Toxoplasmosis 100%
• Infection 75%
• Sequela 75%
• Congenital Toxoplasmosis 75%
• Disease 50%
• Congenital Infection 50%
• Diagnosis 25%
• Chemoprophylaxis 25%
• Visual Impairment 25%
• Primary Prevention 25%
• Infection Rate 25%
• Epileptic Seizure 25%
• Spontaneous Abortion 25%
• Spasticity 25%
• Immunoglobulin M 25%
• Hydrocephalus 25%
• Lymphadenopathy 25%
• Paralysis 25%
• Hearing Impairment 25%
• Subclinical Infection 25%
• Microcephaly 25%
• Sulfonamide 25%
• Secondary Prevention 25%
• Sabin-Feldman Dye Test 25%
• Newborn Disease 25%
• Brain Calcification 25%
• Spiramycin 25%
• Pyrimethamine 25%
• Adolescence 25%
• Gestational Age 25%